Business Description
Armata Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US03211P3010
Total Employee Number:
61Description
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.01 | |||||
Equity-to-Asset | -4.46 | |||||
Debt-to-Equity | -1.2 | |||||
Debt-to-EBITDA | -1.42 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -59.9 | |||||
3-Year EPS without NRI Growth Rate | -62.7 | |||||
3-Year FCF Growth Rate | 10.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 42.69 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.99 | |||||
9-Day RSI | 40.62 | |||||
14-Day RSI | 40.04 | |||||
3-1 Month Momentum % | -32.53 | |||||
6-1 Month Momentum % | -2.61 | |||||
12-1 Month Momentum % | 174.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.64 | |||||
Quick Ratio | 0.64 | |||||
Cash Ratio | 0.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | -65.35 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -349.56 | |||||
ROIC % | -21.78 | |||||
3-Year ROIIC % | -40.4 | |||||
ROC (Joel Greenblatt) % | -526.26 | |||||
ROCE % | -8524.89 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.03 | |||||
EV-to-Forward-EBIT | -13.03 | |||||
EV-to-EBITDA | -2.04 | |||||
EV-to-Forward-EBITDA | -13.03 | |||||
EV-to-Forward-Revenue | 97.38 | |||||
EV-to-FCF | -21.89 | |||||
Earnings Yield (Greenblatt) % | -49.26 | |||||
FCF Yield % | -14.68 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Armata Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -6.682 | ||
| Beta | 3.308 | ||
| 3-Year Sharpe Ratio | 0.93 | ||
| 3-Year Sortino Ratio | 2.31 | ||
| Volatility % | 105.98 | ||
| 14-Day RSI | 40.04 | ||
| 14-Day ATR (€) | 0.3911 | ||
| 20-Day SMA (€) | 4.098 | ||
| 12-1 Month Momentum % | 174.51 | ||
| 52-Week Range (€) | 1.98 - 13.3 | ||
| Shares Outstanding (Mil) | 36.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Armata Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Armata Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-12 | In 101 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 9 days | ||
| General meeting for 2026 | 2026-06-11 08:30 | 6.60 (+3.12%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 7.45 (+0.00%) | ||
| Annual report for 2025 | 2026-03-25 | 7.35 (+4.26%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 7.35 (+4.26%) | ||
| Third quarter earnings results for 2025 | 2025-11-12 | 5.45 (+3.81%) | ||
| H.C. Wainwright 27th Annual Global Investment Conference | 2025-09-10 13:30 | 2.40 (+1.69%) | ||
| Second quarter earnings results for 2025 | 2025-08-12 | 2.04 (+0.00%) | ||
| General meeting for 2025 | 2025-06-12 08:30 | 1.68 (-2.33%) |
Show
Entries
Armata Pharmaceuticals Inc Frequently Asked Questions
What is Armata Pharmaceuticals Inc(STU:TG1N)'s stock price today?
The current price of STU:TG1N is €3.94. The 52 week high of STU:TG1N is €13.30 and 52 week low is €1.98.
When is next earnings date of Armata Pharmaceuticals Inc(STU:TG1N)?
The next earnings date of Armata Pharmaceuticals Inc(STU:TG1N) is 2026-08-12 Est..
Does Armata Pharmaceuticals Inc(STU:TG1N) pay dividends? If so, how much?
Armata Pharmaceuticals Inc(STU:TG1N) does not pay dividend.
Press Release
Articles on Armata Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers